X4 Pharma FY2024 net rev $2.6M; Phase 3 CN trial on track; restructuring cuts spend $30-35M

X4 Pharmaceuticals, Inc

XOLREMDI net product revenue $2.6M from May 2024 launch through YE; cost of revenue $0.8M.
Net loss FY2024 $37.5M (incl. $105M PRV gain); cash $102.8M; pro-forma runway into 1H 2026.
Phase 3 4WARD trial for chronic neutropenia activated at ~90% sites; full enrollment expected Q3/Q4 2025; top-line data 2H 2026.
Protocol amendment: enroll only moderate/severe CN (ANC<1000); co-primary endpoint refined to uniform ANC increase ≥500 cells/µL.
Strategic restructuring reduces annual spend by $30-35M; includes headcount reduction, closing Vienna facility, and right-sizing US team.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.